RecruitingNCT00017914
Neuromuscular
Inclusion Body Myositis
Also known as IBM, sporadic IBM, sIBM
Inclusion Body Myositis is the most common acquired muscle disease in adults over 50, characterised by progressive muscle weakness with a distinctive pattern of finger flexor and quadriceps involvement, often asymmetric. Muscle biopsy shows
ORPHA:611 ↗Prevalence 1 in 14,000 to 1 in 28,000 (most common inflammatory myopathy over age 50)Onset Adults over age 45; mean onset in 6th decadeSporadic (acquired, not inherited)
5
studies recruiting now
as of 7 Sept 2026
64
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
17 Mar 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT06536166
Ruxolitinib Treatment in Inclusion Body Myositis
RecruitingNot applicableNCT07478172
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RecruitingNCT07374107
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
RecruitingEarly phase 1NCT06479863
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Inclusion Body Myositis studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Inclusion Body Myositis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: IBM Natural History Study · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Inclusion Body Myositis
Inclusion Body Myositis is the most common acquired muscle disease in adults over 50, characterised by progressive muscle weakness with a distinctive pattern of finger flexor and quadriceps involvement, often asymmetric. Muscle biopsy shows rimmed vacuoles, congophilic amyloid deposits, and cytoplasmic inclusions containing TDP-43 and p62. The pathogenesis involves both inflammatory and degenerative components, and the disease is refractory to standard immunosuppressive therapy.
Common clinical features
Finger flexor weakness (difficulty gripping, opening jars)Quadriceps weakness causing falls and difficulty rising from chairsAsymmetric muscle weakness patternDysphagia (in up to 60% of patients)Foot dropProgressive loss of ambulation (wheelchair dependency within 10–15 years of onset)Mild facial weakness
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Bimagrumab
Phase 3Sirolimus (Fyarro)
Phase 3Arimoclomol
Phase 2/3Ulviprubart
Phase 2Garetosmab
Phase 2Alemtuzumab (Campath mabcampath)
Phase 2Trevogrumab
Phase 2Ruxolitinib (Jakavi)
+ 4 more in development
Before you apply
Things trial teams commonly ask about for Inclusion Body Myositis. Not eligibility rules; those are set by each study.
- IBM diagnosis must meet ENMC 2011 or 2013 diagnostic criteria (clinico-pathological or clinical IBM); a muscle biopsy report confirming rimmed vacuoles or endomysial inflammation with CD8+ T-cell invasion is usually required
- Anti-cN1A (Mup44) antibody positivity supports diagnosis and may be an eligibility biomarker in some trials; serum samples for antibody testing should be obtained before applying
- Trials frequently use grip strength dynamometry and the IBM Functional Rating Scale (IBMFRS) as primary endpoints; baseline functional scores should be documented
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).